Personalis Inc Stock
Price
Target price
€1.22
€1.22
-3.090%
-0.041
-3.090%
€3.25
24.05.24 / Tradegate
WKN: A2PLTK / Symbol: PSNL / Name: Personalis / Stock / Biotechnology & Medical Research / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Personalis Inc Stock
Personalis Inc took a tumble today and lost -€0.041 (-3.090%).
Personalis Inc is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
With a target price of 3 € there is potential for a 145.5% increase which would mean more than doubling the current price of 1.22 € for Personalis Inc.
Our community identified positive and negative aspects for Personalis Inc stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Personalis Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Personalis Inc in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Personalis Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Personalis Inc | -3.090% | -4.754% | -5.564% | -34.827% | -41.250% | -93.200% | - |
| Stoke Therapeutics Inc | -0.740% | 3.906% | 25.472% | - | - | - | - |
| Immuron | -2.450% | 0.505% | -7.870% | 17.751% | 19.162% | -47.632% | - |
Comments
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
Personalis, Inc. (NASDAQ: PSNL) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $4.00 price target on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
News
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on May 15, 2024, a
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on